Best Brian and Eamonn Podcasts (2024)

1
Leading From Within with ISCT & Kiji's Miguel Forte, M.D. 59:37

1d ago59:37

59:37

We love to hear from our listeners. Send us a message. He's been a big pharma executive. He's a multi-time biotech founder and current biotech CEO. He was once a regulator. He's a physician. He serves on multiple boards. And as of this summer, he's president of one of the most influential global organizations dedicated to the advance of cell and ge…

1
The Allogeneic Future with Poseida's Kristin Yarema, Ph.D. 1:04:44

8d ago1:04:44

1:04:44

We love to hear from our listeners. Send us a message. Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she says CAR T-cell therapies have to become a one-to-many proposition, if their early autologous success can possibly live up to the promise of offering widespread accessibility to life-saving treatments. D…

1
British Invaders 456: After the Warming (Part 2) 26:32

11d ago26:32

26:32

After the Warming was a 1989 speculative documentary from James Burke. Its first episode described the way humans interacted with the climate in the past, while the second episode showed us the events of 1990 through 2050. This two-part production warned us about climate change and the greenhouse effect. Please send us your comments, questions, req…

1
Expanding The Proteome with ProFound's John Lepore, M.D. 56:38

15d ago56:38

56:38

We love to hear from our listeners. Send us a message. Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome, where it’s now studying the full compendium of …

1
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné 1:06:39

22d ago1:06:39

1:06:39

We love to hear from our listeners. Send us a message. While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry, and to go to work as a big bio research sc…

1
British Invaders 455: After the Warming (Part 1) 18:27

23d ago18:27

18:27

After the Warming was a 1989 speculative documentary from James Burke. It was set in the year 2050 and warned us about climate change. Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us on the British Invaders Facebook Group. We are also on Threads and Instagram. Brit…

1
First AI Antibody In Humans with Aulos' Aron Knickerbocker 1:08:52

29d ago1:08:52

1:08:52

We love to hear from our listeners. Send us a message. Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Br…

1
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs 1:12:31

1M ago1:12:31

1:12:31

We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. …

1
British Invaders 454: Quatermass at the Movies (Part 2) 32:22

1M ago32:22

32:22

Hammer Films adapted all three 1950s BBC Quatermass serials as films. The Quatermass Xperiment was released in 1955, Quatermass 2 in 1957 and Quatermass and the Pit in 1967. This is our annual “spinoff” discussion about an adaptation of a British SF TV series into a different medium. Please send us your comments, questions, requests and complaints.…

1
Topical Ocular Biologics with Claris Bio's Clarke Atwell 58:06

1M ago58:06

58:06

We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if succ…

1
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley 1:04:02

2M ago1:04:02

1:04:02

We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting fo…

1
British Invaders 453: Quatermass at the Movies (Part 1) 21:46

2M ago21:46

21:46

Hammer Films adapted the three BBC Quatermass serials as films. They were released to cinemas in 1955, 1957 and 1967. This is our annual “spinoff” discussion about an adaptation of a British SF TV series into a different medium. Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you …

1
True DEI Value in Biopharma with Arcellx's Rami Elghandour 1:04:08

2M ago1:04:08

1:04:08

We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to …

1
Mission-Driven Dementia Funding with DDF's Jonathan Behr 55:46

2M ago55:46

55:46

We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-f…

1
British Invaders 452: Alice in Wonderland (Part 2) 25:27

2M ago25:27

25:27

Alice in Wonderland was a 1986 BBC adaptation of the classic book by Lewis Carroll. Journey from sepia into colour as we enter Wonderland! Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us on the British Invaders Facebook Group. We are also on Threads and Instagram. …

1
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller 1:04:06

2M ago1:04:06

1:04:06

We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership …

1
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D. 56:38

3M ago56:38

56:38

We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, …

1
British Invaders 451: Alice in Wonderland (Part 1) 18:26

3M ago18:26

18:26

Alice in Wonderland was a 1986 BBC adaptation of the classic book by Lewis Carroll. Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us on the British Invaders Facebook Group. We are also on Threads and Instagram. British Invaders is an audio podcast that discusses tel…

1
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch 57:35

3M ago57:35

57:35

We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…

1
A New Prescription For PBMs with Allan Shaw 40:13

3M ago40:13

40:13

We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …

1
British Invaders 450: Krod Mandoon and the Flaming Sword of Fire (Part 2) 21:53

3M ago21:53

21:53

Krod Mandoon and the Flaming Sword of Fire was a sword-and-sorcery comedy from 2009. This co-production from BBC2 and Comedy Central brought us a team of mostly-bumbling adventurers who try to save Hessemeel from the tyrant Chancellor Dongalor! Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gma…

1
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim 59:10

3M ago59:10

59:10

We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …

1
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch 59:11

4M ago59:11

59:11

We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …

1
British Invaders 449: Krod Mandoon and the Flaming Sword of Fire (Part 1) 20:04

4M ago20:04

20:04

Krod Mandoon and the Flaming Sword of Fire was a sword-and-sorcery comedy from 2009. It was a co-production from BBC2 and Comedy Central. Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us on the British Invaders Facebook Group. We are also on Threads and Instagram. B…

1
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D. 1:01:30

4M ago1:01:30

1:01:30

We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…

1
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D. 56:54

4M ago56:54

56:54

We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…

1
British Invaders 448: Stig of the Dump (Part 2) 24:32

4M ago24:32

24:32

Stig of the Dump was a 2002 BBC adaptation of the classic children’s novel by Clive King. Young Barney has discovered a pre-human hominid living by a dump. Where will their friendship lead? Where did “Stig” come from? Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us…

1
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil. 49:47

4M ago49:47

49:47

We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…

1
Funding Alzheimer's Tx Dev with ADDF's Karen Harris 40:16

4M ago40:16

40:16

We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…

1
British Invaders 447: Stig of the Dump (Part 1) 18:46

5M ago18:46

18:46

Stig of the Dump was a 2002 BBC adaptation of the classic children’s novel by Clive King. What will happen when young Barney discovers a prehistoric man living nearby? Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmail.com, and you can find us on the British Invaders Facebook Group. We are al…

1
The AI Impact with Generate:Biomedicines' Mike Nally 1:13:54

5M ago1:13:54

1:13:54

We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersecti…

1
Strategic Deals with CinRx's Gavin Samuels, M.D. 47:52

5M ago47:52

47:52

We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business d…

1
British Invaders 446: Noggin the Nog (Part 2) 28:59

5M ago28:59

28:59

Noggin the Nog was a Smallfilms series that ran from 1959 to 1965 and briefly returned in 1982. Noggin, King of the Nogs befriends a talking bird and an ice dragon! He goes on all sorts of adventures, and tries to thwart his evil uncle Nogbad the Bad. Please send us your comments, questions, requests and complaints. You can reach us at britishinvad…

1
Serial Success With Triumvira's Rob Williamson 31:32

5M ago31:32

31:32

We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson is…

1
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 50:43

5M ago50:43

50:43

We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challen…

1
British Invaders 445: Noggin the Nog (Part 1) 21:23

6M ago21:23

21:23

Noggin the Nog was a Smallfilms series that ran from 1959 to 1965 and briefly returned in 1982. Noggin becomes King of the Nogs and befriends a talking bird and an ice dragon! Can he stop his evil uncle Nogbad the Bad from stealing his throne? Please send us your comments, questions, requests and complaints. You can reach us at britishinvaders@gmai…

1
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D. 40:38

6M ago40:38

40:38

We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necess…

1
Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D. 51:07

6M ago51:07

51:07

We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger w…

Podcasts Worth a Listen

Brian And Eamonn Podcasts

Podcasts Worth a Listen

Quick Reference Guide